Nektar Therapeutics

NASDAQ: NKTR
$4.87
-$0.01 (-0.2%)
Closing price August 8, 2022
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic...
Tuesday's top analyst upgrades, downgrades and initiations included Apollo Global Management, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target and TJX Companies.
These are not the only losers after earnings, but these are the big movers to the downside that also have seen active trading on Friday after the first hour or so of the day.
The top analyst upgrades, downgrades and initiations on Friday included Activision Blizzard, ANGI Home Services, Azul, Baidu, CommScope, E*Trade, Kraft Heinz, Symantec and Uber Technologies.
Tuesday was a positive day for the broad U.S. markets. All of the major exchanges had another solid performance, making this the third consecutive positive trading session amid a bear market. Crude...
The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter &...
Monday was a down day for the broad U.S. markets. Each of the major exchanges started out the week on a negative note, with each seeing a loss of at least 2.0%. Crude oil continued lower yet again,...
Tuesday was a positive day for the broad U.S. markets. Although there seemed to be a lot of uncertainty leading up to this Election Day, it seems the markets are taking it in stride now that it’s...
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Monday was a mixed day for the broad U.S. markets. While all three major indices started out on a positive note, only two of the three finished there. Crude oil started out the week with a bang...
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
These four red-hot Jefferies growth stock picks could have substantial upside, especially if the market simmers down some.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.